SIGA TECHNOLOGIES INC Quarterly Report Released - Here’s What You Should Know

SIGA Technologies, Inc.
Q2 2025 Investor Summary

Key Financial Metrics

• Revenues for Q2 2025 were $81.1 million, a significant increase from $21.8 million in Q2 2024. For the six months ended June 30, 2025, total revenues were $88.2 million, compared to $47.2 million in the prior-year period.
• Product sales and supportive services accounted for $79.1 million in Q2 2025 revenues ($84.9 million for the first half), with research and development contributing $2.0 million ($3.2 million YTD).
• Cost of sales and supportive services was $25.6 million for Q2 2025 ($25.7 million for six months), up from $12.3 million ($15.5 million YTD) in the previous year.
• SG&A expenses for Q2 2025 were $5.5 million ($11.2 million for six months), compared to $5.5 million ($13.4 million YTD) in 2024.
• R&D expenses increased to $4.4 million for Q2 2025 ($7.9 million for six months), up from $2.9 million ($5.9 million YTD) in 2024.
• Net and comprehensive income was $35.5 million for Q2 2025 ($35.1 million YTD), considerably higher than $1.8 million ($12.1 million YTD) in the prior year.
• Basic and diluted income per share was $0.50 and $0.49, respectively, for Q2 2025 ($0.49 for six months), up from $0.03 ($0.17 YTD) in 2024.
• Cash and cash equivalents totaled $182.5 million at June 30, 2025, compared to $155.4 million at year-end 2024.
• Total assets were $235.3 million, and stockholders’ equity was $209.3 million as of June 30, 2025.
• The company paid a special cash dividend of $0.60 per share during the quarter, totaling $43.5 million.

Risks

• Regulatory Risk: Continued market access depends on maintaining existing approvals and obtaining new ones in international jurisdictions. For example, TPOXX® is authorized under "exceptional circumstances" in the EU and UK, and any negative EMA opinion (noting closure of the latest reassessment July 24, 2025) could impact revenues and future market access.
• Supply Chain and Tariff Risk: Future macroeconomic volatility, including U.S.-Europe tariff activity, may materially increase raw material and manufacturing costs for IV TPOXX®. While recent tariffs have not significantly impacted results, future changes could.
• Customer Concentration: The U.S. government, through contracts such as the BARDA contract (base period potential payments of $79.2 million, exercised options up to $545.2 million), remains the primary revenue source. A reduction or delay in government procurement would negatively affect results.
• International Sales Uncertainties: International revenues were $5.8 million YTD, but reliance on amended or renewed International Promotion Agreements introduces additional risk due to regulatory variations and market unpredictability.
• Legal/Regulatory Proceedings: As with most pharmaceutical companies, SIGA is exposed to various claims, suits, and regulatory investigations that could arise and adversely affect its business.

Management Discussion

• Growth Drivers: The significant revenue increase was driven by U.S. government procurement contracts for TPOXX® and a rebound in international sales. BARDA contract options exercised have been substantial, supporting top-line growth.
• Expense Management: SG&A expenses remained stable year-over-year for the quarter and declined over six months, reflecting disciplined cost control. R&D expenses rose due to continued product development, including studies tied to mpox and label expansion for TPOXX®.
• Profitability: Net income rose markedly from both the prior quarter and year-to-date periods, mainly on revenue growth and stable operating costs.
• Cash Flow and Liquidity: Operating cash flows for the six months were $70.1 million (up from a $165,000 use of cash in 2024), strengthening the company’s liquidity and supporting shareholder returns, including the special dividend.
• Outlook: SIGA has notable unexercised BARDA contract options ($5.6 million remaining potential) and ongoing international regulatory activities that may support mid- to long-term revenues. The company continues to prioritize support for public health preparedness with significant U.S. government and emerging international customers.

Conclusion

SIGA Technologies demonstrated robust revenue and profitability growth in Q2 2025, supported by large government contracts and expanding international sales. The company's liquidity position is strong, and operational discipline is evident. Risks include heavy dependence on government contracts, regulatory uncertainties both in the U.S. and internationally, and potential macroeconomic volatility. Investors should monitor regulatory developments, changes to U.S. government procurement, and ongoing supply chain and tariff risks.

Visit Publicview AI to search and analyze millions of SEC filings using AI.